Skip to main content
Caplight Logo









ExoStemTech

ExoStemTech

Private
South KoreaHealthcare & Life Scienceshttps://www.exostemtech.com/

Last Round

Strategic

Dec 1, 2021

Est. Valuation

$71.4M

Total Funding Raised

$12.03M

Company Overview

ExoStemTech is a biotechnology company that develops exosome-based therapeutic systems for tissue repair and regeneration, focusing on conditions such as osteoarthritis, liver fibrosis, and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

exosome therapeuticsregenerative medicinestem cell therapyextracellular vesiclesbiomanufacturingdrug discoverybiotech platformexosome isolationcell-free therapybiopharmaceutical developmentquality control technologynext-gen biologicstherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ExoStemTech Comparables

Compare ExoStemTech with similar companies based on industry and business-model similarity.

ExoStemTech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BREXOGEN Inc.
89%
ILIAS Biologics Inc.
87%
EVerZom
81%

ExoStemTech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicDec 1, 2021
Series BOct 26, 2021

ExoStemTech Investors

Notable investors and investment history

ExoStemTech investors
InvestorRounds
DSC InvestmentSeries B, Series A
Hana SecuritiesSeries B
We VenturesSeries B
IMM InvestmentSeries B, Series A
Laguna InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2021

    Daewoong Pharmaceutical participated in the round.

  • Oct 26, 2021

    $8.4M round led by DSC Investment.

ExoStemTech Filings

Explore SEC and related filing metadata, where available.

ExoStemTech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ExoStemTech's valuation, stock price, and market status.

Is ExoStemTech a public or private company?

ExoStemTech is a private company.

What is the current stock price of ExoStemTech?

ExoStemTech is a private company with no public stock price. No recent secondary market data is available.

How much is ExoStemTech worth (valuation)?

ExoStemTech's valuation is estimated at $71.4M based on funding round data.

Can I buy ExoStemTech stock?

ExoStemTech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ExoStemTech's last funding round?

ExoStemTech's most recent funding round was Strategic on October 26, 2021.

Who are the main investors in ExoStemTech?

Key investors in ExoStemTech include DSC Investment, Hana Securities, We Ventures, IMM Investment, Laguna Investment.

Will ExoStemTech IPO soon?

No public IPO plans have been announced for ExoStemTech.

How can I track ExoStemTech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ExoStemTech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth Korea
Year Founded2016
Last FundingDec 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?